Lakewood-Amedex Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers
Initiation of patient dosing marks a significant clinical development milestone for Nu-3 and Lakewood-Amedex's proprietary Bisphosphocin® antimicrobial platform Lakewood-Amedex…
Newswire
